Currently, Cancer-Free Home Injection has multiple PARP inhibitors currently being recruited for clinical trials, such as htmc0435 (mainly recruiting for gastric cancer, pancreatic cancer, prostate cancer, ovarian cancer, and breast cancer). The indications do not require HRD or BRCA mutations and do not limit mutations.
